| Crohns Disease |
IM101-084,
NCT00406653 |
A Study of Abatacept in Patients With Active Crohn's Disease |
Completed |
Details |
| Immunosuppression |
IM101-042,
NCT00119678 |
Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone |
Completed |
Details |
| Immunosuppression |
IM101-075,
NCT00430677 |
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis |
Active, not recruiting |
Details |
| Immunosuppression |
IM101-217,
NCT00705367 |
Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg |
Active, not recruiting |
Details |
| Immunosuppression |
IM103-010,
NCT00402168 |
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids |
Active, not recruiting |
Details |
| Immunosuppression |
IM103-045,
NCT00555321 |
Belatacept in Liver Transplant Recipients |
Active, not recruiting |
Details |
| Immunosuppression |
IM103-047,
NCT00578448 |
Belatacept Pharmacokinetic Trial in Renal Transplantation |
Active, not recruiting |
Details |
| Immunosuppression |
IM103-056,
NCT00719225 |
A Belatacept Compassionate Use Study for Patients With a Kidney Transplant |
Available |
Details |
| Immunosuppression |
IM103-100,
NCT00035555 |
Study Comparing the Safety and Efficacy of BMS-224818 to Cyclosporine, in Patients Receiving a Kidney Transplant, When Used in Combination With CellCept, Simulect, and Corticosteroids. |
Completed |
Details |
| Leukemia |
MDX1342-02,
NCT00593944 |
Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL) |
Suspended |
Details |
| Multiple Sclerosis |
IM101-200,
NCT00035529 |
A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis |
Terminated |
Details |
| Pharmacokinetics |
IM101-017,
NCT00277199 |
Comparability DE vs CD-CHO1 |
Completed |
Details |
| Psoriasis |
IM101-001,
NCT00306878 |
Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris |
Completed |
Details |
| Psoriasis |
IM101-003,
NCT00277225 |
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris |
Completed |
Details |
| Psoriasis |
IM101-005,
NCT00287547 |
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris |
Completed |
Details |
| Psoriasis |
IM117-005,
NCT00162253 |
Study of BMS-587101 in Patients With Moderate to Severe Psoriasis |
Terminated |
Details |
| Psoriasis |
IM119-013,
NCT00399906 |
A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis |
Completed |
Details |
| Psoriatic Arthritis |
IM101-158,
NCT00534313 |
Safety and Efficacy of Abatacept Versus Placebo in Subjects With Psoriatic Arthritis |
Active, not recruiting |
Details |
| Rheumatoid Arthritis |
IM101-015,
NCT00162201 |
An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy |
Completed |
Details |
| Rheumatoid Arthritis |
IM101-023,
NCT00122382 |
Remission and Joint Damage Progression in Early Rheumatoid Arthritis |
Completed |
Details |
| Rheumatoid Arthritis |
IM101-029,
NCT00048581 |
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past. |
Completed |
Details |
| Rheumatoid Arthritis |
IM101-031,
NCT00048932 |
A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis |
Completed |
Details |
| Rheumatoid Arthritis |
IM101-033,
NCT00095173 |
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis |
Active, not recruiting |
Details |
| Rheumatoid Arthritis |
IM101-043,
NCT00095147 |
Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis |
Completed |
Details |
| Rheumatoid Arthritis |
IM101-046,
NCT00124449 |
Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients |
Completed |
Details |
| Rheumatoid Arthritis |
IM101-049,
NCT00279734 |
Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers |
Completed |
Details |
| Rheumatoid Arthritis |
IM101-063,
NCT00254293 |
Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After SC Administration to Subjects With RA |
Active, not recruiting |
Details |
| Rheumatoid Arthritis |
IM101-064,
NCT00124982 |
Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy |
Completed |
Details |
| Rheumatoid Arthritis |
IM101-071,
NCT00345748 |
A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate |
Completed |
Details |
| Rheumatoid Arthritis |
IM101-100,
NCT00162266 |
CTLA4IG With Methotrexate- Phase IIB - Long Term |
Completed |
Details |
| Rheumatoid Arthritis |
IM101-101,
NCT00162279 |
The Study of Abatacept in Combination With Etanercept |
Completed |
Details |
| Rheumatoid Arthritis |
IM101-102,
NCT00048568 |
A Phase III Study of BMS-188667 in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate |
Completed |
Details |
| Rheumatoid Arthritis |
IM101-119,
NCT00420199 |
A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate |
Completed |
Details |
| Rheumatoid Arthritis |
IM101-124,
NCT00409838 |
A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis, With an Inadequate Response to Methotrexate |
Completed |
Details |
| Rheumatoid Arthritis |
IM101-129,
NCT00484289 |
A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis |
Active, not recruiting |
Details |
| Rheumatoid Arthritis |
IM101-167,
NCT00533897 |
Phase IIIB Subcutaneous Missed Dose Study |
Active, not recruiting |
Details |
| Rheumatoid Arthritis |
IM101-173,
NCT00547521 |
Phase IIIB Subcutaneous Abatacept Monotherapy Study |
Active, not recruiting |
Details |
| Rheumatoid Arthritis |
IM101-174,
NCT00559585 |
Methotrexate-Inadequate Response Study |
Active, not recruiting |
Details |
| Rheumatoid Arthritis |
IM101-179,
NCT00767325 |
A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography |
Recruiting |
Details |
| Rheumatoid Arthritis |
IM101-185,
NCT00663702 |
Phase IIIB Switching From Intravenous to Subcutaneous Study |
Active, not recruiting |
Details |
| Rheumatoid Arthritis |
IM101-235,
NCT00929864 |
Abatacept Versus Adalimumab Head-to-Head |
Recruiting |
Details |
| Rheumatoid Arthritis |
IM101-250,
NCT01001832 |
Efficacy, Pharmacokinetics, Safety and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japan |
Recruiting |
Details |
| Rheumatoid Arthritis |
IM103-002,
NCT00279760 |
Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis |
Completed |
Details |
| Rheumatoid Arthritis |
IM119-010,
NCT00162292 |
Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background |
Completed |
Details |
| Rheumatoid Arthritis |
IM119-014,
NCT00570752 |
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis |
Recruiting |
Details |
| Rheumatoid Arthritis |
IM119-015,
NCT00605735 |
PoC in Rheumatoid Arthritis With Methotrexate |
Completed |
Details |
| Rheumatoid Arthritis |
MDX1100-04,
NCT01017367 |
Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA) |
Completed |
Details |
| Rheumatoid Arthritis |
MDX1342-01,
NCT00639834 |
Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis |
Suspended |
Details |
| Transplantation |
IM103-008,
NCT00256750 |
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) |
Active, not recruiting |
Details |
| Transplantation |
IM103-027,
NCT00114777 |
Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant |
Active, not recruiting |
Details |
| Transplantation |
IM103-034,
NCT00455013 |
A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation |
Active, not recruiting |
Details |
| Transplantation |
IM103-046,
NCT00569803 |
Subcutaneous Pharmacokinetics Study |
Completed |
Details |
| Ulcerative Colitis |
IM101-108,
NCT00410410 |
A Study of Abatacept in Patients With Active Ulcerative Colitis |
Completed |
Details |
| Ulcerative Colitis |
MDX1100-01,
NCT00295282 |
A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis |
Completed |
Details |
| Ulcerative Colitis |
MDX1100-06,
NCT00656890 |
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis |
Completed |
Details |
| Undifferentiated Arthritis |
IM101-226,
NCT01142726 |
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA) |
Not yet recruiting |
Details |